Irvine-based Urovant Sciences Ltd., a maker of overactive bladder medication, appointed Walt Johnston to the role of senior VP of commercial, while electing James Hindman to its board of directors.
Johnston, who has 30 years of industry experience, will assist new Chief Executive James Robinson in commercializing the company’s flagship pharmaceutical “to help drive the potential of vibegron and Urovant’s entire pipeline,” Robinson said in a statement.
Hindman said he’s joining the board at a “promising juncture in the company’s history following its filing of the vibegron new drug application with the FDA.”
Hindman served as chief financial officer of then Irvine-based Allergan until its $70.5 billion sale to Actavis PLC in 2015.
CEO Change
Executive changes are a recurring theme of late for Urovant; in April Robinson replaced founder and CEO Keith Katkin, who has remained as an adviser.
Robinson was recently president and chief operating officer Paragon Biosciences LLC; he was also CEO at Qlarity Imaging LLC, a Paragon portfolio company.
Johnston previously served as senior VP of the Urology and Hospital Business unit at Illinois-based Astrellas Pharma, where he spent the past 12 years.
Urovant went public in 2018 at a price of $14 a share; its shares are down some 30% this year and now trade at about $11.50, giving the firm a $350 million market cap.
